Preconception immunization with a cytomegalovirus (CMV) glycoprotein vaccine improves pregnancy outcome in a guinea pig model of congenital CMV infection.
The guinea pig (gp) model of congenital cytomegalovirus (CMV) infection was used to evaluate a gpCMV glycoprotein vaccine. Hartley guinea pigs were immunized 3 times with 50 microg of lectin column-purified glycoproteins prepared from gpCMV-infected or -uninfected tissue culture. Immunization with the gpCMV vaccine produced seroconversion in all animals. Animals then were placed with gpCMV-seronegative male animals and were challenged late in pregnancy with virulent salivary gland-passaged gpCMV. Immunization with gpCMV glycoproteins significantly improved pregnancy outcome, with 54 of 63 pups live-born in immunized animals, compared with 21 of 48 in the controls (P<.001). In addition, virus was isolated from 24 of 54 live-born pups born to immunized mothers, compared with 16 of 20 live-born pups born to controls, indicating that immunization significantly reduced in utero transmission in surviving animals (P<.01).
Bourne
N
N
Children's Hospital Medical Center, Division of Infectious Diseases, Cincinnati, Ohio 45229, USA. bourn0@chmcc.org
Schleiss
M R
MR
Bravo
F J
FJ
Bernstein
D I
DI
D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000151:congenital / Q000517:prevention & control*; D004195:Disease Models, Animal; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage / Q000276:immunology; D006168:Guinea Pigs; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D011247:Pregnancy; D011256:Pregnancy Outcome; D014611:Vaccination; D022223:Vaccines, Subunit; D014765:Viral Vaccines / Q000008:administration & dosage*
D000914:Antibodies, Viral; D006023:Glycoproteins; D022223:Vaccines, Subunit; D014765:Viral Vaccines